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Background: The natural history of abdominal aortic aneurysms (AAAs) suggests that some remain slow in growth rate
whereas many develop a more accelerated growth rate and reach a threshold for intervention. We hypothesized that
different mechanisms are responsible for AAAs that remain slow growing and never become actionable vs the aggressive
AAAs that require intervention and may be reﬂected by distinct associations with genetic polymorphisms.
Methods: AAA growth rate was determined from serial imaging data in 168 control and 141 AAA patients with ultrasound
or computed tomography imaging studies coveringw5 years. Genetic polymorphisms all previously reported as showing
a signiﬁcant correlation with AAA with functional effects on the expression or function were determined by analysis of the
genomic DNA, including angiotensin 1 receptor (rs5186), interleukin-10 (IL-10; rs1800896), methyl-tetrahydrofolate
reductase (rs1801133), low-density lipoprotein receptor-related protein 1 (LRP1; rs1466535), angiotensin-converting
enzyme (rs1799752), and several matrix metalloproteinase 9 (MMP-9) single nucleotide polymorphisms.
Results: Of the AAA patients, 81 were classiﬁed as slow AAA growth rate (<3.25 mm/y) vs 60 with aggressive AAA
growth rate (>3.25 mm/y, those presenting with a rupture, or those with maximal aortic diameter >5.5 cm [male] or
>5.0 cm [female]). Discriminating confounds between the groups were identiﬁed by logistic regression. Analyses iden-
tiﬁed MMP-9 p-2502 single nucleotide polymorphism (odds ratio [OR], 0.54; 95% conﬁdence interval [CI], 0.31-0.94;
P [ .029) as a signiﬁcant confound discriminating between control vs slow-growth AAA, MMP-9 D165N (OR, 0.49;
95% CI, 0.26-0.95; P[ .035) and LRP1 (OR, 4.99; 95% CI, 1.13-22.1; P[ .034) between control vs aggressive-growth
AAAs, and methyltetrahydrofolate reductase (OR, 2.99; 95% CI, 1.01-8.86; P[ .048), MMP-9 p-2502 (OR, 2.19; 95%
CI, 1.05-4.58; P[ .037), and LRP1 (OR, 4.96; 95% CI, 1.03-23.9; P[ .046) as the statistically signiﬁcant confounds
distinguishing slow-growth AAAs vs aggressive-growth AAAs.
Conclusions: Logistic regression identiﬁed different genetic confounds for the slow-growth and aggressive-growth AAAs,
indicating a potential for different genetic inﬂuences on AAAs of distinct aggressiveness. Future logistic regression studies
investigating for potential genetic or clinical confounds for this disease should take into account the growth rate and size
of the AAA to better identify confounds likely to be associated with aggressive AAAs likely to require intervention. (J Vasc
Surg 2014;60:613-21.)Abdominal aortic aneurysm (AAA), once thought to
affect 6% of men aged >60 years and responsible for
>2% of all deaths, has shown a recent decline in the
incidence in many parts of the world, although the
reported decrease in the incidence is not uniform
throughout the world.1 Nevertheless, rupture of AAA
remains a high mortality event and is often the ﬁrst
manifestation of the disease.2 Identiﬁcation of presymp-
tomatic patients with an AAA and those likely to prog-
ress to a disease state requiring intervention remainstheMolecular andCellular Pharmacology Graduate Program, University
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The precise pathophysiology of AAA remains contro-
versial, but progression of the disease can be divided into
four steps: aneurysm initiation, formation, growth, and
rupture.3 The growth rate of AAA correlates with the
size of the aneurysm on presentation, indicating that
growth accelerates as the aneurysm enlarges.4,5 The AAA
growth rate is increased in smokers, whereas it is decreased
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Table I. The known functional consequences of genetic variations under studya
Gene rs# Polymorphism Location Functional alteration Reference (ﬁrst author)
ACE rs1799752 287 bp Ins Intron Inc enzymatic activity Rigat16
AT1R rs5186 A>C 30UTR Inc receptor density Martin17
IL-10 rs1800896 G>A Promoter Dec promoter activity Bown18
LRP1 rs1466535 C>T Intron Inc receptor density Bown14
MMP-9 (p-2502) rs8113877 G>T Promoter Dec promoter activity Duellman15
MMP-9 (p-2118) rs3918240 C>T Promoter Inc promoter activity Duellman15
MMP-9 (p-1702) rs3918241 T>A Promoter Dec promoter activity Duellman15
MMP-9 (D165N) rs8125581 G>A Exon Dec enzymatic activity Duellman15
MMP-9 (R279Q) rs17576 G>A Exon Inc enzymatic activity Duellman15
MMP-9 (R668Q) rs17577 G>A Exon Inc enzymatic activity Duellman15
MTHFR rs1801133 C>T Exon Dec enzymatic activity Sharp19
ACE, Angiotensin-converting enzyme; AT1R, angiotensin 1 receptor; bp Ins, base pair insertion; Dec, decrease; IL-10, interleukin-10; Inc, increase; LRP1,
low-density lipoprotein receptor-related protein 1; MMP-9, matrix metalloproteinase 9; MTHFR, methyl-tetrahydrofolate reductase.
aGenetic polymorphisms demonstrating signiﬁcant correlationwithAAA according to recentmeta-analyses were selected. Additionally,MMP-9 single nucleotide
polymorphisms (SNPs) identiﬁed in our recent study were selected. The gene affected, the rs# polymorphism identiﬁcation number, actual genetic polymorphism
where the major allele>SNP allele, location and the functional alterations of the polymorphism when known, and the literature references are listed.
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AAAs $5.5 cm (5.0 cm for women) or those demon-
strating a fast growth rate serve as a threshold for surgical
intervention.4,9 A clinical indicator or a biomarker of
aggressive AAAs likely to progress to requiring intervention
is currently lacking.
A genetic component to AAA was ﬁrst documented by
the observation that a positive history of AAA in a ﬁrst-
degree relative increased the risk of AAA by 10-fold.10 Sus-
ceptibility genes for AAA are considered likely predisposing
factors, but no pathogenic genes responsible for AAA have
been identiﬁed. The disease is likely multifactorial,
involving multivariable interactions among numerous
genes and environmental factors. A recent analysis of a
cohort of >3 million individuals has reconﬁrmed male
sex, hypertension, hypercholesterolemia, history of smok-
ing, and a history of coronary artery disease as clinical
risk factors associated with AAA.11
Various investigators have studied polymorphisms of
speciﬁc genes encoding key molecules thought to be
involved in AAA formation, primarily focusing on genes
encoding structural proteins of the vessel wall, degrading
enzymes, such as matrix metalloproteinases (MMPs), tissue
inhibitors of MMPs, immunomodulatory molecules, and
molecules involved in hemodynamic stress consistent with
our current understanding of the pathogenesis of AAA.
An AAA is often asymptomatic before rupture and occurs
in older patient populations, making the establishment of
large cohorts for genetic association studies difﬁcult.
Reassessment of the literature by recent meta-ana-
lyses3,12,13 of allelic-association case-control studies have
identiﬁed a number of potential genetic variation predispo-
sitions associated with AAA but suffer the limitation of sta-
tistically analyzing data obtained from different cohorts of
individuals. In the current study, we sought to reassess
the genotype association of ﬁve genetic variations that
have been reported as demonstrating a signiﬁcant correla-
tion with AAA in a well-deﬁned single population of cases
and controls. The AAA individuals all had multiple imagingstudies to allow assessment of the aneurysm growth
rate, allowing us to classify them as slow-growth or fast-
growth AAAs. Speciﬁcally, we performed a case-control lo-
gistic regression analysis of angiotensin-converting enzyme
(ACE; rs1799752), angiotensin 1 receptor (AT1R; (rs5186),
interleukin-10 (IL-10; rs1800896), and methyl-
tetrahydrofolate reductase (MTHFR; rs1801133), all of
which were reported in meta-analysis studies as showing
signiﬁcant correlation with AAA. We also included low-
density lipoprotein receptor-related protein 1 (LRP1;
rs1466535), reported as showing association with AAA
in a recent genome-wide association study14 and several
MMP-9 single nucleotide polymorphisms (SNPs; p-
2502 [rs8113877], p-2118 [rs3918240], p-1702
[rs3918241], D165N [rs8125581], R279Q [rs17576],
and R668Q [rs17577]) with demonstrated effects on
the expression or function of this protease and with sufﬁ-
cient minor allele frequency in the northern Wisconsin
population, as we recently reported.15
METHODS
Selection of genetic variations included in the cur-
rent study. The genetic variations (four SNPs and one
deletion) selected for this study were identiﬁed by recent
meta-analyses to show signiﬁcant association with AAA
and had also been reported to result in well-deﬁned func-
tional alterations of the gene products. A brief summary of
the known functional consequences of the selected genetic
variations is presented in Table I. Supplementary Table I
(online only) lists the published studies cited in the meta-
analyses and the genotype distribution of the SNPs
included in the current analysis. In addition, we included
six MMP-9 SNPs with functional consequence on the
expression or function of this molecule.
We worked under the assumption that a given genetic
variation may contribute to the association with AAA only
if the underlying genetic variation resulted in a functional
alteration of the gene expression or function. This
approach provides a context with which to demonstrate
Table II. Demographic and clinical variables of controls and abdominal aortic aneurysm (AAA) participants
Clinical variablea
Control
(n ¼ 168)
Slow AAA
(n ¼ 81)
Pb
Agg AAA
(n ¼ 60) Slow vs control Agg vs control Agg vs slow
Date of birth,c year 1929.97 6 0.60 1930.19 6 0.88 1929.57 6 0.99 .853 .731 .640
Male gender 74 80 67 .371 .250 .100
Body mass index, kg/m2 29.3 6 0.4 28.8 6 0.5 29.2 6 0.8 .395 .856 .627
Smoking .652 .830 .593
Never 18 15 17
Current 20 17 23
Former 62 68 60
Coronary artery disease 58 68 53 .123 .555 .079
Age at diagnosis, year 71.7 6 0.9 69.2 6 1.0 70.5 6 1.7 .080 .533 .505
Hypertension 94 94 92 .945 .523 .621
Age at diagnosis, year 63.4 6 0.9 63.0 6 1.4 64.0 6 1.5 .787 .747 .637
Hypercholesterolemia 83 88 80 .374 .636 .216
Age at diagnosis, year 62.5 6 0.8 61.7 6 1.2 62.9 6 1.3 .597 .817 .534
Scans, No. NA 7.33 6 0.52 6.37 6 0.54 NA NA .202
Growth rate, R2 NA 0.70 6 0.03 0.69 6 0.05 NA NA .927
Follow-up duration, year NA 5.66 6 0.53 4.10 6 0.64 NA NA .065
Max aortic dimension, cm 1.80 6 0.07d 4.30 6 0.12 6.24 6 0.19 <.001e <.001e <.001e
Growth rate, mm/y NA 1.08 6 0.08 5.10 6 0.55 NA NA <.001e
Agg, Aggressive; NA, not applicable; R2, correlation coefﬁcient for the linear regression of the growth curve.
aContinuous data are presented as mean 6 standard error and nominal variables are displayed as a percentage of the total.
bP values were determined by a Student t-test for ordinate variables and by a c2 test for proportions.
cDate of birth rather than the current age was used because the former is a better measure of age at the entry of the subjects into the Personalized Medicine
Research Project (PMRP) database and a better measure allowing direct comparison between the cases and controls in this retrospective database study. Date
of birth is given as year and a decimal value corresponding to the month/12.
dThe maximum abdominal aortic dimension for the control group is based on 66 individuals with reported abdominal aortic dimensions stated on the imaging
reports and no members of this group had any mention of abdominal aortic abnormality on at least one imaging study of the abdominal aorta.
eIndicates statistical signiﬁcance (P < .05).
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genetic association with AAA.3
Selection of cases and controls. The Marshﬁeld
Clinic Personalized Medicine Research Project (PMRP)
was established in 2001 and currently has a collection of
>20,000 patients with clinical information and genomic
DNA available.20 The PRMP database21 was searched
with a sole inclusion criterion of patients with a diagnosis of
aortic aneurysm (International Classiﬁcation of Diseases,
Ninth Revision, code between 441.3 and 441.5) at two
dates and at least one conﬁrmatory scan (magnetic reso-
nance imaging, contrast computed tomography [CT], or
angiography) of the AAA with a maximal dimension
measurement of $3 cm or at least one AAA rupture
diagnosis code. Exclusion criteria included history of syn-
dromic connective tissue diseases (eg, Marfan and Ehlers-
Danlos syndromes), presence of any nonaortic aneurysms,
abdominal trauma, and syphilis. The cohort did not have
sufﬁcient data to discriminate individuals with inﬂamma-
tory vs atherosclerotic AAA21 or those with potential
mycotic aneurysms. The same exclusion criteria were
applied to the control population derived from individuals
enrolled in the PMRP.
Because the participants are selected from a well-
deﬁned patient population conﬁrmed for the presence of
AAA by imaging studies, the incidence is 100% for this
case-control genetic analysis, circumventing loss of statisti-
cal power due to misdiagnosed individuals. The controlparticipants had no diagnoses of AAA and must have had
at least one scan with no aortic measurements >2.5 cm.
The well known confounds for AAA, such as male sex, pa-
tient age, hypertension, hypercholesterolemia, history of
coronary artery disease, and history of smoking were fre-
quency matched in the selection of the controls to maxi-
mize detection of unaccounted genetic contribution to
the disease (Table II). The recently documented negative
correlation between AAA and diabetes was not known
when this study was initiated, and the history of diabetes
or the use of antihyperglycemic medication was not
abstracted for the current cohort.
Of the 168 AAA individuals available in the database,
we restricted our model development to 141 with multiple
imaging studies with a median follow-up duration of
5.06 years. We used the available serial imaging data to
classify those to 81 with slow-growth AAA (mean growth
rate of 1.08 6 0.08 mm/y) vs 24 with fast-growth AAA
(mean growth rate of 5.10 6 0.55 mm/y) based on the
threshold growth rate of 3.25 mm/y (Table II). These
AAA growth rates are well within the range reported in a
large meta-analysis.4 An aggressive-AAA group was deﬁned
as those with a fast-growth rate, those with a maximal
aneurysm dimension >5.5 cm (men) or 5.0 cm (women),
or those presenting with a rupture (n ¼ 9). In this sense,
we use the term aggressive-AAA to describe a group of pa-
tients where the disease has become actionable or has pro-
gressed to the threshold of intervention.
Fig. Analysis of aneurysm growth rates in the abdominal aortic
aneurysm (AAA) cohort. A, Maximum aortic diameter from one
individual assessed by computed tomography (CT; square) and
ultrasound imaging (circle) plotted as a function of age. Both
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the database, 32 were included in the aggressive-AAA
group based on the growth rate (before intervention) or
the aneurysm size inclusion criteria. The remaining seven
were excluded due to insufﬁcient information to allow
determination of the aneurysm growth rate. This allowed
logistic regression modeling of possible contribution of
the genetic confounds for control (n ¼ 168) vs slow-
growth AAA (n¼ 81), or aggressive-AAA (n¼ 60) compar-
isons. The transfer of genomic DNA from the Marshﬁeld
Clinics to University of Wisconsin Madison and genotyping
was approved by the University of Wisconsin Institutional
Review Board protocol M2010-1315.
Genotyping and variable number of tandem repeats
determination. Genomic DNA of the case and control
participants was genotyped for the SNPs of interest
by the University of Wisconsin Biotechnology Center
using the KASP method (http://www.lgcgenomics.com/
genotyping/kasp-genotyping-chemistry/kasp-overview/)
with the primers listed in Supplementary Table II (online
only). Genotyping was repeated for ambiguous calls,
resulting in detection of all genotypes for all subjects. For
rs1799752 (ACE1) with a 287-bp insertion/deletion
polymorphism, a target DNA encompassing the poly-
morphism was ampliﬁed by polymerase chain reaction using
a 6-carboxyﬂuorescein-tagged forward and a reverse
primer, and the product size determined on a capillary
electrophoresis instrument (Applied Biosystems, Foster
City, Calif). The polymerase chain reaction ampliﬁcation
using Titanium Taq DNA polymerase (Clontech Lab,
Mountain View, Calif) consisted of an initial melt at 95C
for 1 minute, followed by 38 cycles of 95C for 1 minute,
59C for 1 minute, 72C for 1 minute, and a terminal
extension at 72C for 10 minutes.
Determination of AAA growth rate. Serial imaging
data, either ultrasound or CT, were available for the individ-
uals with AAA, with a mean follow-up duration of 5 years.
Both imaging techniques demonstrated consistent estimationimaging methods gave consistent measurements of the aneurysm
growth rate and R2 of the linear regression. B, Maximum aortic
diameter vs age is shown for two AAA patients, one with aggressive
(Agg; square) and one with slow (circle) growth rates. C, Distri-
bution of growth rates in the present cohort of 141 individuals
with serial imaging data of their AAAs. Symbols represent a subset
of individuals presenting with an acute AAA rupture (star),
repaired by intervention (open circle), and those above the diam-
eter threshold (triangle). The use of a linear curve ﬁtting could
result in an underestimate of a curvilinear growth rate reported by
some, but our preliminary analysis showed no signiﬁcant increase
in the correlation coefﬁcient (R2 statistics) of exponential over
linear curve ﬁt.D, Patient aneurysm growth rate was binned, and a
threshold of 3.25 mm/y was set to discriminate between aneu-
rysms with slow-growth and fast-growth rates. Ruptured (regard-
less of the size or rate of growth) or repaired aneurysms (above the
growth rate or diameter threshold) were included in the
aggressive-growth rate cohort but not in the double Gaussian ﬁt of
the growth rate.
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ture,22 and ultrasound and CT data were merged in the
subsequent analysis. Although not observed in this cohort,
others have reported that the estimateofAAAdiameter byCT
may be systematically larger than by ultrasound.5
The maximum aortic dimension determined by serial
imaging studies was plotted against time to estimate the
growth rate of the aneurysm by a linear regression through
the data points. A linear regression through multiple imag-
ing data should reduce much of the effect of interobserver
variability in the measurement of aortic dimensions.23
Examples for two individuals, one demonstrating a fast-
growth rate (3.94 mm/y) and a second with a slow-
growth rate (0.52 mm/y) are shown in Fig, B. From the
distribution of aneurysm growth rates, a threshold of
3.25 mm/y was used for deﬁning slow vs fast AAA growth
rate (Fig, C and D). The overall R2 value for the linear
regression for growth rate estimation of the 141 individuals
was 0.69 6 0.03 and was not improved by an exponential
ﬁt, indicating that a linear estimate was adequate for our
current data set. We did not observe the episodic AAA
growth of “ﬁts and starts,” especially for nondiabetic
patients, described in the literature,7 but our analysis of
growth rate would correspond to a linear time-averaged
growth rate if the growth rate were not smooth over time.
Descriptive statistics and logistic regression
modeling. Hardy-Weinberg equilibrium and linkage
disequilibrium (LD) were calculated between each pair of
SNPs based on observed and expected genotypes using
the LD function in R Project software (The R Foundation
for Statistical Computing, http://www.r-project.org/
foundation/; Supplementary Fig 1, online only).
Descriptive statistics of genotype distributions were
determined for cases and controls for additive (AA ¼ 2,
Aa ¼ 1, aa ¼ 0), dominant (AA ¼ 1, Aa or aa ¼ 0), and
recessive (AA or Aa ¼ 1, aa ¼ 0) coding, where A is the
major (wild-type) allele and a is the SNP allele. A c2 statis-
tic was used to determine potential difference in the pro-
portions of genotypes in cases and controls. Coding
demonstrating the most signiﬁcant difference between
the cases and controls for the ﬁve polymorphisms examined
here plus the six functionally signiﬁcant MMP-9 SNPs
identiﬁed in our previous work were tested for AAA asso-
ciation using logistic regression using the generalized
linear model function in R software based on the bino-
mial family and coefﬁcients of regression considered sig-
niﬁcant for P < .05. The form of the ﬁtted equation
was: ln(P/1eP) ¼ A0 þ S Ai  rsi, where P is the prob-
ability of AAA, A0 is the intercept (ie, outcome not
accounted for by the confounds), Ai is the regression co-
efﬁcient, and rsi is the genetic variant confound, with no
interaction terms allowed due sample size limitations.
According to this coding, the odds ratio (OR) calculated
is with respect to the wild-type allele. Determination of
whether to keep or eliminate a given confound in the
logistic regression was based on a likelihood ratio test
using the analysis of variance function (test ¼ “Chisq”
option) in R software.A reduced model was compared with the full model
before the confound reduction, and the eliminated
confound was considered an insigniﬁcant contributor to
the overall ﬁt if the likelihood ratio test resulted in P >
.05. We chose the above ad hoc approach rather than the
frequently used automatic selection of the confounds by
a stepwise regression technique using Akaike information
criteria because of the unresolved statistical meaning and
the validity of this approach.24,25 The performance of the
derived logistic regression model in its ability to correctly
classify true positive (beneﬁt) from false positive (cost)
was evaluated by the receiver operating characteristic
(ROC) curve and the area under the curve (AUC)26 using
the ROC function (epidemiology [Epi] package; R Proj-
ect). Cross-validation of the model was performed by a
10-fold cross validation (sometimes called rotation estima-
tion),27 of the same data set used for the model develop-
ment using the cv.binary function (Data Analysis and
Graphics [DAAG] package; R Project). Statistical inference
for the individual coefﬁcients and OR of the ﬁnal logistic
regression model were based on a large sample approxima-
tion to the sample distribution where standard error (SE)
of the estimate SE ¼ sqrt (S1/ni) where ni are the
numbers of observed data entries in a 2  2 contingency
table.28
RESULTS
At the time of study initiation, the cohort of 141 indi-
viduals with information on AAA growth rate divided into
slow-growth and fast-growth rates were matched to con-
trols for the clinical confounds of age, sex, history of coro-
nary artery disease, hypertension, hypercholesterolemia,
and smoking known to show association with AAA
(Table II).
The demographic and clinical variables for this cohort
have been published previously and only differ in the
maximum aortic dimension as expected (Fig 3, A in Duell-
man et al15). The ﬁve new genetic variants examined were
in Hardy-Weinberg equilibrium, with no signiﬁcant LD
with each other (Supplementary Fig 1, online only), sug-
gesting the potential for these confounds to show indepen-
dent association with AAA. The overall distribution of the
genotypes for the 168 controls and 141 AAA patients for
additive, dominant, and recessive coding are reported in
Table III. Of note is the observation that none of the con-
founds by themselves, regardless of the coding, demon-
strated statistically signiﬁcant c2 statistics (P < .05) or
unadjusted ORs (95% conﬁdence intervals excluding 1.0)
in our cohort, including all AAAs in apparent contradiction
to the previously published results in the literature
(Supplementary Table I, online only).
Logistic regression analysis between controls without
aneurysms vs the slow-growth rate AAA group identiﬁed
MMP-9p-2502 as the only statistically signiﬁcant (P <
.05) confounds (Table IV).The ROC analysis revealed an
AUC of 0.60, indicating that this model was only a mod-
erate discriminator against control vs slow-AAA groups.
A 10-fold cross validation demonstrated an accuracy of
Table III. Genetic variations in control and abdominal aortic aneurysm (AAA) individuals
Gene Codinga Genotype
Case (n ¼ 141),
No. (%)
Control (n ¼ 168),
No. (%) OR (95% CI) Pb
ACE Additive DD 45 (32) 43 (25) .39
DI 69 (49) 85 (51) 1.29 (0.76-2.18) .34
II 27 (19) 40 (24) 1.55 (0.82-2.95) .18
Dominant DD 45 (32) 43 (26) 1.36 (0.83-2.24) .22
DIþII 96 (68) 125 (74)
Recessive DDþDI 114 (81) 128 (76) 1.32 (0.76-2.29) .32
II 27 (19) 40 (24)
AT1R Additive AA 73 (52) 77 (46) .52
AC 54 (38) 75 (45) 1.32 (0.82-2.12) .26
CC 14 (10) 16 (9) 1.08 (0.49-2.38) .20
Dominant AA 73 (52) 77 (46) 1.27 (0.81-1.99) .30
ACþCC 68 (48) 91 (54)
Recessive AAþAC 127 (90) 152 (90) 0.95 (0.45-2.03) .90
CC 14 (10) 16 (10)
IL-10 Additive AA 42 (30) 48 (29) .71
AG 60 (42) 77 (46) 1.25 (0.73-2.16) .41
GG 39 (28) 43 (25) 1.20 (0.66-2.19) .55
Dominant AA 42 (30) 48 (29) 1.23 (0.75-2.03) .41
AGþGG 99 (70) 120 (71)
Recessive AAþAG 102 (72) 125 (74) 1.05 (0.64-1.72) .86
GG 39 (28) 43 (26)
LRP1 Additive CC 66 (47) 67 (40) .32
CT 62 (44) 78 (46) 1.24 (0.77-2.00) .38
TT 13 (9) 23 (14) 1.74 (0.81-3.73) .15
Dominant CC 66 (47) 67 (40) 1.33 (0.84-2.09) .22
CTþTT 75 (53) 101 (60)
Recessive CCþCT 128 (91) 145 (86) 1.56 (0.76-3.21) .22
TT 13 (9) 23 (14)
MTHFR Additive CC 66 (47) 79 (47) .71
CT 53 (37) 68 (40) 1.07 (0.66-1.74) .28
TT 22 (16) 21 (13) 0.80 (0.40-1.58) .51
Dominant CC 66 (47) 79 (47) 0.99 (0.63-1.55) .97
CTþTT 75 (53) 89 (53)
Recessive CCþCT 119 (84) 147 (87) 0.77 (0.41-1.47) .43
TT 22 (16) 21 (13)
ACE, Angiotensin-converting enzyme; AT1R, angiotensin 1 receptor; CI, conﬁdence interval; IL-10, interleukin-10; Inc, increase; LRP1, low-density
lipoprotein receptor-related protein 1; MTHFR, methyl-tetrahydrofolate reductase; OR, odds ratio.
aGenotypes of the indicated single nucleotide polymorphisms (SNPs) and insertion/deletion polymorphism for ACE1 were determined and tabulated as
additive coding (AA ¼ 2, Aa ¼ 1, aa ¼ 0), dominant coding (AA ¼ 1, Aa or aa ¼ 0), and recessive coding (AA, or Aa ¼ 1, aa ¼ 0).
bThe P value is the c2 statistics for the contingency table. For the additive coding AA vs Aa and AA vs aa were both calculated from the respective 2  2
contingency table.
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revealed MMP-9 D165N (P ¼ .035) and LRP1 (P ¼
.034) as statistically signiﬁcant associations, with an AUC
of 0.60 and 10-fold cross validation of 0.74 (Table IV).
Lastly, we sought genetic associations able to potentially
discriminate between AAAs with slow growth rate and
aggressive growth rate because this distinction has critical
clinical importance. A logistic regression model demon-
strated the statistically signiﬁcant association of MTHFR
(P ¼ .048), MMP-9p-2502 (P ¼ .037), and LRP1 (P ¼
.046; Table IV). The AUC of the ROC curve was 0.65,
demonstratingmoderate discrimination between the groups
and a 10-fold cross-validation estimate of accuracy of 0.62.
DISCUSSION
The speciﬁc genetic variations in ACE (rs1799752),
AT1R (rs5186), IL-10 (rs1800896), and MTHFR
(rs1801133) considered in the current study have allbeen reported to show correlation with AAA recapitulated
in recent meta-analyses, and LRP1 (rs1466535) has also
been shown to associate with AAA in a genome-wide asso-
ciation study. These genetic variants all result in known al-
terations of the gene expression or function, or both, and
could play a plausible role in AAA based on our current un-
derstanding of the pathobiology of AAA. The surveillance
of small AAAs has demonstrated that some individuals
with this disease remain stable for an extended time with
a slow aneurysm growth rate, whereas others demonstrate
aggressive increases in aneurysm size or require surgical
intervention on presentation. Diabetes decreases AAA
growth rate,4,7 and drugs, such as cholesterol-lowering
drugs and the antibiotic doxycycline, have been reported
to decrease the AAA expansion rate, although a recent
meta-analysis concluded that no single drug used for car-
diovascular risk reduction had a major effect on the growth
or rupture of small aneurysms.5
Table IV. Results of logistic regression of the genetic confoundsa
Slow AAA vs control ROC AUC: 0.60
PCovariates Coding Coefﬁcient 6 SE Adjusted OR (95% CI)
Constant 0.23 6 0.39 1.25 (0.59-2.67) .558
MMP-9 p-2502 Recessive 0.62 6 0.28 0.54 (0.31-0.94) .029b
MTHFR Recessive 0.67 6 0.36 0.51 (0.25-1.04) .065
Aggressive AAA vs control ROC AUC: 0.60
PCovariates Coding Coefﬁcient 6 SE Adjusted OR (95% CI)
Constant 2.01 6 0.76 0.13 (0.03-0.60) .008b
MMP-9 D165N Dominant 0.71 6 0.34 0.49 (0.26-0.95) .035b
LRP1 Recessive 1.61 6 0.76 4.99 (1.13-22.10) .034b
Slow AAA vs aggressive AAA ROC AUC: 0.65
PCovariates Coding Coefﬁcient 6 SE Adjusted OR (95% CI)
Constant 3.23 6 0.98 0.04 (0.01-0.27) <.001b
MTHFR Recessive 1.10 6 0.56 2.99 (1.01-8.86) .048b
MMP-9 p-2502 Recessive 0.79 6 0.38 2.19 (1.05-4.58) .037b
LRP1 Recessive 1.60 6 0.80 4.96 (1.03-23.92) .046b
AAA, Abdominal aortic aneurysm; AUC, area under curve; CI, conﬁdence interval; LRP1, low-density lipoprotein receptor-related protein 1;MMP-9, matrix
metalloproteinase 9; MTHFR, methyl-tetrahydrofolate reductase; OR, odds ratio; ROC, receiver operating characteristic; SE, standard error.
aThe acronyms for the genetic polymorphisms are as described in the Methods. The genetic coding indicates the coding used for the logistic regression
resulting in the coefﬁcients, the adjusted OR (95% CI) and the P value, and ROC AUC (see Methods) was calculated as a measure of the model’s ability to
discriminate the two groups being compared.
bIndicates statistical signiﬁcance.
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 3 Duellman et al 619However, no studies have investigated the association
of genetic confounds with cohorts of AAA patients group-
ed by growth rate. We investigated the association between
genetic polymorphisms and AAA participants with slow
growth rate (growth rate <3.25 mm/y) and aggressive
growth rate subgroups (growth rate >3.25 mm/y, pre-
senting with a rupture, or aortic size exceeding the
accepted threshold for intervention).
A control vs slow-growth AAA comparison revealed
signiﬁcant association of MMP-9 and a trend toward signif-
icance for MTHFR. MMP-9, which targets elastin and
collagen for degradation, has been long considered a key
contributor in the pathophysiology of AAA in the initiation
of aortic wall inﬂammation, followed by the proteolytic
degradation and attenuation of the mechanical support of
the aorta.29,30 Increases in elastin and collagen degradation
products have shown a positive correlation with aortic dila-
tion, with potential utility as a circulating biomarker for
aneurysm progression.31 A promoter SNP at p-2502
(rs8113877) in the MMP-9 gene decreases the transcrip-
tional activity15; therefore, the wild-type genotype with
normal transcriptional activity carries an increased risk.
MTHFR is the primary enzyme for homocysteine meta-
bolism. The C>T polymorphism (rs1801133) causes an
alanine-to-valine substitution in the protein that results in
a 70% reduction in enzyme activity, as measured in vitro,
and manifests in vivo as a raised homocysteine level.19
High homocysteine levels induce serine proteases in
vascular smooth muscle cells and cause alterations inarterial vasculature,32 induce elastolysis in vitro through
the action of MMP-2,33 and clinically correlate with AAA
patients selected for surgical treatment.34 As such, the
MTHFR wild-type genotype with normal enzymatic activ-
ity and a lower homocysteine level will be protective
compared with the SNP. Both genotype associations with
slow-growth AAA revealed in this analysis demonstrate
mechanistic feasibility.
The control vs fast-growth AAA comparison revealed a
signiﬁcant correlation with a different MMP-9 D165N and
a LRP1 SNP. The MMP-9 D165N SNP (rs8125581)
located in the coding exon results in a decreased enzymatic
activity,15 and a negative-association with AAA makes
functional sense. The LRP1 SNP (rs1466535) is located
in the second intron of LRP1 with no known nonsynony-
mous SNPs or splice-site variants in LD with this site.
There was a signiﬁcant increase in LRP1 expression in
CC (wild-type) compared with TT (SNP) homozygotes
potentially involving the transcription factor sterol regula-
tory element-binding protein 1.14,35 LPR1 has multiple li-
gands with a wide variety of biological activity, including
effects on vascular smooth muscle cell migration and prolif-
eration36 and regulation of inﬂammation status, both
proinﬂammatory and anti-inﬂammatory, through interac-
tion with transforming growth factor-b and regulation of
MMP-9, tumor necrosis factor-a, inducible nitric oxide
synthase, and IL-6.37,38
The biological role of LRP1 in AAA is unknown at this
time, but we speculate, based on the increased OR for the
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ysis, that the overall effect of LRP1 is protective against
an aggressive growth rate in AAA. The MTHFR SNP in
conjunction with the MMP-9 p-2502 SNP and LRP1
affords a distinction between AAA individuals with slow-
growth vs aggressive-growth rate. This information is
particularly important because identiﬁcation of the
aggressive-growth rate subset of the AAA cohort will allow
a closer interval of follow-up imaging and possibly earlier
intervention before the AAA expands to a point with a
signiﬁcantly increased risk.
The clinical or economic utility of genetic stratiﬁcation
of AAA cannot be assessed without further studies, but the
cost of genotyping is trivial (w$50 per genotype)
compared with the cost of even a single abdominal ultra-
sound scan (w$1600) or CT scan (w$5400), according
to cost estimates derived from customary charges at the
University of Wisconsin hospital, including the scan and
professional read fee (personal communication from Lor-
ene Seman, Department of Radiology, February 10,
2014). Further outcome studies are needed to see whether
genetic screening can ever replace the currently standard
imaging methods.
Lastly, we wish to comment on the apparent discrep-
ancy in the unadjusted OR observed in our cohort and
those previously published. A failure to replicate genetic as-
sociation studies is a well-recognized problem with several
potential reasons, including confounding from population
structure, misclassiﬁcation of outcome, inappropriate
matching of clinical confounds, and allelic heterogeneity.39
Alternatively, the inability to replicate may be due to a true
heterogeneity in the genetic basis of the disease being
considered. Our cohort was derived from a well-studied
group of individuals with stringent criteria for entry for
both patients and controls, including radiographic data,
and is unlikely to suffer from misclassiﬁcation of outcome
at the time of data collection. However, because AAA
largely affects older individuals, it is possible that the con-
trol participants could develop AAA later in life, which
was unaccounted for. Confounding factors from popula-
tion structure, such as other genetic and environmental
factors, and allelic heterogeneity leading to different path-
ogenic mechanisms for different populations, are essentially
impossible to assess when comparing results from one
cohort with those from another. That allelic heterogeneity
exists between ethnic groups is well known, and this infor-
mation is now available for many genes through the Inter-
national HapMap Project database (hapmap.ncbi.nlm.nih.
gov). Supplementary Fig 2 (online only) shows the known
cohort-dependent minor allele frequency of ﬁve SNP vari-
ations for which information is available. The minor allele
frequencies of some genetic polymorphisms show consider-
able cohort-dependent differences, suggesting a strong
allelic heterogeneity in the population documented in the
HapMap Project database.
Meta-analyses, despite well-recognized weaknesses,
have contributed toward circumventing the severe limita-
tion of small sample size of individual studies by combiningdata of multiple studies through statistical techniques.40
However, future meta-analyses should consider the estab-
lished fact of population variation in SNPs as well as the
population from which the primary data arose and group
the data for statistical analysis only when the populations
show similar distribution of the genotype being investi-
gated. This simple consideration should reduce group
stratiﬁcation error and the risk of over-extrapolating ge-
netic association results from multiple studies derived
from different populations.
CONCLUSIONS
The statistical power of our current study is restricted
by the small sample size; nevertheless, our result offer a
genetic polymorphism association as a method to segregate
patients with AAA where the disease is likely to remain
benign with a slow growth rate and those likely to require
intervention. A future replication study to conﬁrm and vali-
date the ﬁndings of our current study should be drawn
from an analogously well-deﬁned population to reduce
the risk of group stratiﬁcation error.
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Supplementary Fig 1 (online only). The ﬁve genetic poly-
morphisms show little linkage disequilibrium (LD). Additional
genes chosen for genetic associate studies show minor LD with
each other. LD is displayed as the D index, with 0 showing no
linkage and 1 indicating perfect linkage. LD for the matrix
metalloproteinase-9 (MMP-9) single nucleotide polymorphism
(SNP) was reported in Duellman et al (2012).16 ACE,
Angiotensin-converting enzyme; AT1R, angiotensin 1 receptor;
IL-10, interleukin-10; LRP1, low-density lipoprotein receptor-
related protein 1; MTHFR, methyl-tetrahydrofolate reductase.
Supplementary Fig 2 (online only). Population-dependent variation in theminor allele frequency of genetic variations
derived from the International HapMap (Haplotype Mapping) database. The bars are minor allele frequency
retrieved from the HapMap database and calculated from the observed genotypes for our local patient cohort
(Wisc), of the genes showing signiﬁcant association with abdominal aortic aneurysm (AAA) based on multivariate
logistic regression analysis. ACE, Angiotensin-converting enzyme; AT1R, angiotensin 1 receptor; IL-10, interleukin-
10; LRP1, low-density lipoprotein receptor-related protein 1; MMP-9, matrix metalloproteinase-9; MTHFR, methyl-
tetrahydrofolate reductase.
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Supplementary Table I (online only). Summary of published genetic polymorphism distributions in abdominal aortic
aneurysm (AAA)a
Gene Alleles (rs#)
Study
(ﬁrst author)
Case
(No.)
Cont
(No.)
Case
(MAF)
Cont
(MAF)
OR
(95% CI) Coding Region
Adj OR
(95% CI)
ACE I/D Fatini3 250 250 0.63 0.49 1.90 (1.3-2.9) Dominant Italy 2.4 (1.3-4.2)
NR Pola4 56 112 0.82 0.46 6.88 (3.38-14.02)b Dominant Italy NA
Hamno5 125 153 0.40 0.42 1.12 (0.62-2.03)b Dominant Japan NA
Korcz6 133 152 0.45 0.51 0.50 (0.20-1.25) Dominant Poland 0.92 (0.40-2.10)
ACE I/D Jones7
(rs4646994) Population 1 576 472 0.54 0.54 1.07 (0.78-1.47)b Recessive NZ 1.28 (0.82-1.98)
Population 2 298 912 0.52 0.50 1.32 (0.96-1.80)b Recessive UK 1.26 (0.83-1.92)
Population 3 352 339 0.53 0.49 1.24 (0.88-1.75)b Recessive Australia 1.40 (0.87-2.27)
ACE I/D Current study 133 168 0.44 0.49 1.59 (0.82-3.08) Additive US NA
(rs4646994)
AT1R A1166C Fatini3 250 250 0.30 0.28 1.41 (0.72-2.76) Recessive Italy NA
(rs5168) Jones7
Population 1 576 472 0.30 0.27 1.31 (1.02-1.68)b Recessive NZ 1.52 (0.85-2.75)
Population 2 298 912 0.34 0.27 1.57 (1.21-2.05)b Recessive UK 1.79 (1.07-2.99)
Population 3 352 339 0.37 0.29 1.57 (1.13-2.18)b Recessive Australia 1.89 (1.02-3.50)
Current study 133 168 0.31 0.32 1.13 (0.73-1.78) Dominant US NA
IL-10 A1082G Bown8 100 100 0.59 0.47 1.80 (0.92-3.64) A allele England NA
(rs1800896) Bown9 389 404 0.53 0.45 1.50 (1.09-2.07) A allele England 1.45 (0.84-1.92)
Current study 133 168 0.47 0.49 1.20 (0.70-2.06) Additive US NA
LRP1 CC Bown10 6228 49,182 0.32 0.40 1.15 (1.10-1.21) C allele Europe NA
(rs1466535) Current study 133 168 0.32 0.37 1.28 (0.87-2.02) Dominant US NA
MTHFR C677T Brunelli11 58 60 0.48 0.39 0.69 (0.31-1.55)b Dominant Italy NA
(rs1801133) Jones12 428 282 0.31 0.31 1.06 (0.79-1.44)b Dominant NZ 1.12 (0.56-2.22)
Ferrara13
>60 years 42 45 0.57 0.23 0.24 (0.10-0.61)b Dominant Italy NA
<60 years 46 45 0.78 0.23 0.09 (0.03-0.24) Dominant Italy NA
Soﬁ14 438 438 0.43 0.38 0.78 (0.59-1.03) Dominant Italy NA
Strauss15 63 75 0.21 0.37 0.27 (0.13-0.54)b Dominant Poland 0.27 (0.13-0.54)
Current study 133 168 0.37 0.33 0.65 (0.34-1.23) Recessive US NA
ACE, Angiotensin-converting enzyme; Adj. OR, adjusted odds ratio; AT1R, angiotensin 1 receptor; CI, conﬁdence interval; Cont, control; IL-10, interleukin
10; LRP1, low-density lipoprotein receptor-related protein 1; MAF, minor allele frequency; MTHFR, methyl-tetrahydrofolate reductase; NA, not available;
NR, not reported; NZ, New Zealand; UK, United Kingdom; US, United States.
aThe primary literature cited in the meta-analyses1,2 was reviewed, and pertinent information summarized in this Table. Some studies did not unambiguously
specify the polymorphism under study by explicitly stating the polymorphism identiﬁcation number (rs#), the genetic coding used for the model building was
variable, and the different studies involved different subject populations.
bIndicates the OR was calculated based on published case vs control genotype frequencies.
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Supplementary Table II (online only). List of primers used for genotyping the single nucleotide polymorphisms
(SNPs) and polymerase chain reaction polymerase chain reaction detection of the insertion/deletion genetic varianta
KASP primers for genotyping
rs1801133 (C/T SNP) MTHFR
Fwd: GAAGGTGACCAAGTTCATGCTAAAGCTGCGTGATGATGAAATCGG
Rev: GAAGGTCGGAGTCAACGGATTGAAAAGCTGCGTGATGATGAAATCGA
Common: CTTTGAGGCTGACCTGAAGCACTT
rs1800896 (G/A SNP) IL-10
Fwd: GAAGGTGACCAAGTTCATGCTCAACACTACTAAGGCTTCTTTGGGAA
Rev: GAAGGTCGGAGTCAACGGATTAACACTACTAAGGCTTCTTTGGGAG
Common: GAGGTCCCTTACTTTCCTCTTACCTA
rs5186 (A/C SNP) AT1R
Fwd: GAAGGTGACCAAGTTCATGCTTTCTCCTTCAATTCTGAAAAGTAGCTAAT
Rev: GAAGGTCGGAGTCAACGGATTCTCCTTCAATTCTGAAAAGTAGCTAAG
Common: CCTCTGCAGCACTTCACTACCAAAT
rs1466535 (C/T SNP) LRP1
Fwd: GAAGGTGACCAAGTTCATGCTCAGGGTCCATGGCAGAGAAAC
Rev: GAAGGTCGGAGTCAACGGATTGCAGGGTCCATGGCAGAGAAAT
Common: CTGCAACCTGGGAGCTATGGGAA
VNTR primer for PCR
rs1799752 (287 bp deletion) ACE1
Fwd: CTGGAGACCACTCCCATCCTTTCT
Rev: GATGTGGCCATCACATTCGTCAGAT
VNTR, Variable number tandem repeat.
aKASP genotyping was performed for SNP genotyping which includes two SNP-speciﬁc primers, one common primer, and reporter-oligonucleotides
speciﬁcally annealing to the 50 overhang sequence speciﬁc to the one or other SNP-speciﬁc product. The Table lists the SNP-speciﬁc and the common
primers. Further information on this method can be found at http://www.lgcgenomics.com/genotyping/kasp-genotyping-chemistry/kasp-overview/. The
insertion/deletion polymorphism was distinguished using primers designed to polymerase chain reaction amplify the polymorphic region resulting in different
sizes of the ampliﬁcation product.
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